{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-077372","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2024-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.213957+00:00","generated_at":"2026-05-31T23:45:17.732144+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Carisma terminates Novartis manufacturing deal for CT-0508; pays $4M fee, suspends Phase 1 enrollment","bullets":["Terminated Manufacturing and Supply Agreement with Novartis for CT-0508; effective July 31, 2024.","Will pay $4.0M termination fee to Novartis in Q3 2024, with potential credit if Substitute Product transferred by Dec 31, 2024.","Suspends enrollment of new patients in Phase 1 trial for CT-0508 to focus ex vivo oncology on follow-on candidate CT-0525.","Revised operating plan narrows pipeline, prioritizing CT-0525 over CT-0508."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-077372","json":"https://secwatch.observer/filing/0001104659-24-077372.json","markdown":"https://secwatch.observer/filing/0001104659-24-077372.md","text":"https://secwatch.observer/filing/0001104659-24-077372.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924077372/0001104659-24-077372-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924077372/tm2418685d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:45:17.732144+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}